Clinical Benefit of Vagus Nerve Stimulation for Epilepsy: Assessment of Randomized Controlled Trials and Prospective Non-Randomized Studies

AdultPediatric
Written By Rodrigo Silva

Cramer SW, McGovern RA, Chen CC, Park MC.

J Cent Nerv Syst Dis. 2023 Jan 11;15:11795735231151830.
https://doi.org/10.1177/11795735231151830

This study by Cramer et al. (Jan. 2023) examined the efficacy and safety of vagus nerve stimulation (#VNS) for drug-resistant epilepsy (#DRE) by analyzing outcomes from randomized controlled trials (#RCTs) and a prospective, non-randomized study. The RCT studies confirmed a higher seizure frequency reduction in high-frequency VNS settings (>20 Hz) compared to low-frequency VNS settings (1 Hz). Moreover, a prospective, non-randomized study was identified and reviewed regarding the improvement of quality of life (#QoL) for DRE patients using VNS Therapy.

Link to the article: 

https://journals.sagepub.com/doi/10.1177/11795735231151830?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed


Rodrigo Silva
Previous

Vagus nerve stimulation for intractable epilepsy in tuberous sclerosis complex
Next

The role of vagus nerve stimulation in genetic etiologies of drug-resistant epilepsy: a meta-analysis.